Q4 2020 13F Holders as of 12/31/2020
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
212M
-
Number of holders
-
211
-
Total 13F shares, excl. options
-
78M
-
Shares change
-
-3.51M
-
Total reported value, excl. options
-
$1.22B
-
Value change
-
-$2.07M
-
Put/Call ratio
-
0.54
-
Number of buys
-
99
-
Number of sells
-
-91
-
Price
-
$15.61
Significant Holders of SANGAMO THERAPEUTICS, INC - Common Stock (SGMO) as of Q4 2020
269 filings reported holding SGMO - SANGAMO THERAPEUTICS, INC - Common Stock as of Q4 2020.
SANGAMO THERAPEUTICS, INC - Common Stock (SGMO) has 211 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 78M shares
of 212M outstanding shares and own 36.78% of the company stock.
Largest 10 shareholders include WASATCH ADVISORS INC (10.1M shares), BlackRock Inc. (9.57M shares), VANGUARD GROUP INC (8.45M shares), STATE STREET CORP (6.38M shares), CREDIT SUISSE AG/ (3.41M shares), GOLDMAN SACHS GROUP INC (2.48M shares), DIMENSIONAL FUND ADVISORS LP (2.36M shares), GEODE CAPITAL MANAGEMENT, LLC (1.81M shares), JPMORGAN CHASE & CO (1.78M shares), and NORTHERN TRUST CORP (1.44M shares).
This table shows the top 211 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.